Online inquiry

IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7908MR)

This product GTTS-WQ7908MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CSF2 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000758.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1437
UniProt ID P04141
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7908MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12182MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MORAb-022
GTTS-WQ4205MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BIIB019
GTTS-WQ1786MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ4359MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-188667
GTTS-WQ3912MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BCD-135
GTTS-WQ4465MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-901608
GTTS-WQ7473MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GBR-830
GTTS-WQ12401MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA NI-0401
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW